Physician profile
Antonio Caracta
NPI 1508927013
$12,774.86
in general payments reported to CMS, 2019-2025
27 companies · $622 in 2025
The $622 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,586 · 2020: $2,328 · 2021: $2,955 · 2022: $1,088 · 2023: $1,763 · 2024: $1,432 · 2025: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,817.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,978.68 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $1,868.17 | 2019-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $1,844.98 | 2019-2025 | |
| Amgen INC. | $1,728.73 | 2019-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,132.23 | 2019-2025 | Jardiance |
| Pfizer INC. | $790.77 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $669.95 | 2019-2024 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $461.29 | 2020-2021 | |
| Novo Nordisk INC | $356.53 | 2020-2024 | Ozempic, Rybelsus, Wegovy |
| Biogen, INC. | $321.36 | 2021-2024 | Vumerity |
| Tg Therapeutics, INC. | $249.70 | 2023-2024 | |
| Horizon Therapeutics Plc | $241.74 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $129.89 | 2023 | Verquvo |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| Abbvie INC. | $124.96 | 2023 | Qulipta, Ubrelvy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $124.84 | 2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $121.67 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $106.81 | 2021-2023 | |
| Emd Serono, INC. | $103.74 | 2021 | |
| Esperion Therapeutics, INC. | $103.09 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $53.00 | 2019 | |
| Exact Sciences Corporation | $39.63 | 2023-2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $27.38 | 2020-2022 | |
| Amarin Pharma, INC. | $21.87 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $18.39 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $16.75 | 2019 | |
| Allergan, INC. | $13.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Caracta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.